StreetInsider.com News Articles

Form 8-K Quantumzyme Corp. For: Nov 30

Fri, 13 Feb 2026 17:20:00 -0500

si-local-file:///var/storage/secattach/20260213/26002063.html

Form 8-K Quantumzyme Corp. For: Nov 30

Fri, 13 Feb 2026 17:20:00 -0500

si-local-file:///var/storage/secattach/20260213/26002063.html

Quantumzyme Research Published in the Journal of Molecular Graphics & Modelling Study Highlights In Silico Enzyme Engineering Approach for Sustainable Drug Manufacturing

Thu, 12 Feb 2026 07:30:00 -0500

SAN DIEGO, CA - February 12, 2026 (NEWMEDIAWIRE) - Quantumzyme Corp. (OTC: QTZM) (the Company), a biotransformation company focused on sustainable enzyme-based solutions, today announced the publication of its latest research in the Journal of Molecular Graphics & Modelling . The peer-reviewed study describes the Companys application of a fully in silico enzyme engineering approach to support the design and evaluation of biocatalysts prior to laboratory validation.

The publication examines whether enzyme variants can be computationally optimized before experimental testing. In the study, Quantumzyme applied virtual screening and computational modeling techniques to evaluate transaminase enzyme variants used in the asymmetric

Quantumzyme Research Published in the Journal of Molecular Graphics & Modelling Study Highlights In Silico Enzyme Engineering Approach for Sustainable Drug Manufacturing

Thu, 12 Feb 2026 07:30:00 -0500

Quantumzyme Research Published in the Journal of Molecular Graphics & Modelling Study Highlights In Silico Enzyme Engineering Approach for Sustainable Drug Manufacturing

Thu, 12 Feb 2026 07:30:00 -0500

Quantumzyme Research Published in the Journal of Molecular Graphics & Modelling Study Highlights In Silico Enzyme Engineering Approach for Sustainable Drug Manufacturing

Thu, 12 Feb 2026 07:30:00 -0500

Quantumzyme to Attend 2026 BIO International Convention

Wed, 28 Jan 2026 07:30:00 -0500

SAN DIEGO, CA - January 28, 2026 (NEWMEDIAWIRE) - Quantumzyme Corp. (OTC: QTZM) , a biotransformation company focused on enzyme-based solutions for pharmaceutical manufacturing, today announced that it plans to attend the 2026 BIO International Convention , to be held June 2225, 2026, in San Diego, California.

The BIO International Convention is a global gathering of biotechnology and life sciences companies, academic institutions, and industry participants representing a broad range of scientific and commercial disciplines.

Representatives of Quantumzyme expect to attend the conference and engage in informal networking meetings with industry participants. The Company will not be presenting, exhibiting, sponsoring,

Quantumzyme to Attend 2026 BIO International Convention

Wed, 28 Jan 2026 07:30:00 -0500

Representatives of Quantumzyme expect to attend the conference and engage in informal networking meetings with industry participants. The Company will not be presenting, exhibiting, sponsoring,

Form DEF 14C Quantumzyme Corp. For: Jan 15

Thu, 15 Jan 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260115/25855597.html

Form DEF 14C Quantumzyme Corp. For: Jan 15

Thu, 15 Jan 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260115/25855597.html

Form 8-K Quantumzyme Corp. For: Nov 30

Wed, 07 Jan 2026 16:27:00 -0500

si-local-file:///var/storage/secattach/20260107/25820535.html

Form 8-K Quantumzyme Corp. For: Nov 30

Wed, 07 Jan 2026 16:27:00 -0500

si-local-file:///var/storage/secattach/20260107/25820535.html

Form 10-Q Quantumzyme Corp. For: Oct 31

Mon, 15 Dec 2025 16:53:00 -0500

si-local-file:///var/storage/secattach/20251215/25741443.html

Form 10-Q Quantumzyme Corp. For: Oct 31

Mon, 15 Dec 2025 16:53:00 -0500

si-local-file:///var/storage/secattach/20251215/25741443.html

Quantumzyme to Engage With Industry Leaders at BioLogic Summit 2026, Reinforcing Commitment to AI-Driven Innovation

Thu, 04 Dec 2025 09:00:00 -0500

SAN DIEGO, CA - December 4, 2025 (NEWMEDIAWIRE) - Quantumzyme Corp. (OTC: QTZM), a biotransformation company focused on sustainable pharmaceutical manufacturing, today announced that its team is planning to attend the second annual BioLogic Summit, taking place January 19-22, 2026, in San Diego. The summit is a premier event focused on the application of machine learning and artificial intelligence for the design and optimization of biotherapeutics.

Quantumzymes participation underscores its strategic commitment to remaining engaged in the rapidly evolving fields of AI-enabled enzyme engineering and protein design. The conference offers an opportunity for the companys scientific leadership to participate in

Quantumzyme to Engage With Industry Leaders at BioLogic Summit 2026, Reinforcing Commitment to AI-Driven Innovation

Thu, 04 Dec 2025 09:00:00 -0500

Quantumzyme seeks name change to Quantum Genesis AI

Mon, 01 Dec 2025 08:40:46 -0500

Quantumzyme Corp. (OTC: QTZM) announced its board of directors approved a proposed corporate name change to Quantum Genesis AI Corp. The biotechnology company will submit the required notice to the Financial Industry Regulatory Authority, which will include a request to update its ticker symbol.

The proposed change requires FINRA approval before taking effect. The San Diego-based company said the rebranding reflects its strategic intent to align its identity with expanding integration of artificial intelligence into enzyme engineering initiatives.

"While the name change remains subject to regulatory approval, the proposed identity of Quantum Genesis AI represents the direction in which our research and

Quantumzyme seeks name change to Quantum Genesis AI

Mon, 01 Dec 2025 08:40:46 -0500

"While the name change remains subject to regulatory approval, the proposed identity of Quantum Genesis AI represents the direction in which our research and

Quantumzyme seeks name change to Quantum Genesis AI

Mon, 01 Dec 2025 08:40:46 -0500

"While the name change remains subject to regulatory approval, the proposed identity of Quantum Genesis AI represents the direction in which our research and

Quantumzyme seeks name change to Quantum Genesis AI

Mon, 01 Dec 2025 08:40:46 -0500

"While the name change remains subject to regulatory approval, the proposed identity of Quantum Genesis AI represents the direction in which our research and

Quantumzyme Announces Board Approval for Strategic Name Change to Quantum Genesis AI

Mon, 01 Dec 2025 08:40:00 -0500

SAN DIEGO, CA - December 1, 2025 (NEWMEDIAWIRE) - Quantumzyme Corp. (OTC: QTZM), a pioneering biotransformation company revolutionizing pharmaceutical manufacturing through sustainable enzyme-based solutions, today announced that its Board of Directors has approved a proposed corporate name change to Quantum Genesis AI Corp. The Company will now submit the required notice to the Financial Industry Regulatory Authority (FINRA), which will include a request to update its ticker symbol. The proposed change will take effect only following FINRA approval.

The proposed rebranding reflects the Companys strategic intent to align its identity more closely with its expanding integration of artificial intelligence into

Quantumzyme Announces Board Approval for Strategic Name Change to Quantum Genesis AI

Mon, 01 Dec 2025 08:40:00 -0500

The proposed rebranding reflects the Companys strategic intent to align its identity more closely with its expanding integration of artificial intelligence into

Quantumzyme Announces Board Approval for Strategic Name Change to Quantum Genesis AI

Mon, 01 Dec 2025 08:40:00 -0500

The proposed rebranding reflects the Companys strategic intent to align its identity more closely with its expanding integration of artificial intelligence into

Quantumzyme Announces Board Approval for Strategic Name Change to Quantum Genesis AI

Mon, 01 Dec 2025 08:40:00 -0500

The proposed rebranding reflects the Companys strategic intent to align its identity more closely with its expanding integration of artificial intelligence into

Quantumzyme to Showcase Sustainable Enzyme Engineering Innovations at CCE-2026

Wed, 19 Nov 2025 09:00:00 -0500

SAN DIEGO, CA - November 19, 2025 (NEWMEDIAWIRE) - Quantumzyme Corp. (OTCQB: QTZM), a global leader in computational enzyme engineering, today announced its participation in the Catalysis and Chemical Engineering Conference (CCE-2026) , taking place March 911, 2026 , in Boston, MA . At the event, the company will present how its enzyme engineering platform is reshaping traditional chemical synthesis and enabling sustainable, cost-efficient pathways for pharmaceutical manufacturing.

Quantumzymes presence at CCE-2026 reflects its expanding role in advancing green chemistry solutions for the biomanufacturing sector, as global demand grows for low-waste, energy-efficient pharmaceutical production.

Quantumzyme will highlight its latest advancements